Relypsa (RLYP) Debt Financing Removes Overhang - Cantor

Cantor Fitzgerald reiterated a Buy rating and $42 price target on Relypsa, Inc. (NASDAQ: RLYP) saying the $150 million debt financing removes an overhang on the stock.

"The timing - ahead of the ZS-9 PDUFA later this month - and the terms, we believe, are advantageous... We continue to like the shares in spike of volatility given our view that late 3Q:16 is likely to be the inflection for point for Veltassa, and that the longer-term commercial future of the drug is bright."

For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.

Shares of Relypsa, Inc. closed at $17.32 yesterday.

You May Also Be Interested In

• BridgeBio Pharma (BBIO) PT Raised to $115 at Piper Sandler as 'Attruby Outperforms'
• Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY), Highlights Improved Cash Conversion
• Gencor Industries (GENC) PT Raised to $19 at Freedom Broker